Last Updated : July 28, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Lemtrada | Alemtuzumab | Multiple sclerosis, relapsing-remitting | List with criteria/condition | Complete | ||
Lemtrada | Alemtuzumab | Multiple sclerosis, relapsing-remitting | Withdrawn | |||
Lenvima | Lenvatinib | Hepatocellular Carcinoma (HCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Lenvima | Lenvatinib | Differentiated Thyroid Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Lenvima | Lenvatinib | Renal Cell Carcinoma (RCC) | Do not reimburse | Complete | ||
Lenvima and Keytruda | lenvatinib and pembrolizumab | advanced or metastatic renal cell carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Leqembi | lecanemab | Alzheimer’s disease | Active | |||
Leqvio | inclisiran | Primary hypercholesterolemia | Do not reimburse | Active | ||
Leqvio | inclisiran | Primary hypercholesterolemia | Active | |||
Leqvio | inclisiran | Primary hypercholesterolemia | Do not reimburse | Complete |